Under the terms of the license, Allezoe gains the exclusive worldwide rights to this new "see and treat" technology, which will allow healthcare providers to detect cell damage from HPV.
SureScreen Medical, a wholly-owned subsidiary of Allezoe, and AVM, has signed an exclusive license to develop and market products worldwide using the technology in return for a fixed royalty to AVM.
Allezoe CEO Michael Gelmon said the new licensed technology provides accuracy with efficiency in diagnosing human papillomavirus.
